Work

FIGURE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Year: 2024

Type: other

Abstract: The left panels show the number of CD4+ T cells (top) and CD8+ T cells (bottom) over time, separated by responders (CR+PR, solid circles) versus nonresponders (SD+PD, open circles). The right panels show the percentage of effector T cells over time, with CD4+IFNγ+ T cells (top) and CD8+IFNγ+ T cells (bottom). Plot is mean value and error bars show ± 1 SE. The * shows the statistically significant increase in CD4+IFNγ+ T cells in responders versus nonresponders (P = 0.047). X-axis is assessment at baseline (bsl), after cycle 3 (C3), and after cycle 6 (C6).

DOI: 10.1158/2767-9764.25288991

Authors: Rhonda L. Bitting, Janet A. Tooze, Michael Goodman, Donald C. Vile, Jessica M. Brown, Christopher Y. Thomas, Morgan Neve, Mitra Kooshki, Safoa Addo, Pierre L. Triozzi, Purnima Dubey

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4392156084

Cites:

Cited by:

Related to: 10